Guerbet's Vectorio for Interventional Oncology Is Approved in Canada

By News Release

Guerbet, a global leader in medical imaging, announces the registration of Vectorio, kit for imaging of hepatocellular carcinoma (HCC), in Canada.

Vectorio is a set of Lipiodol resistant medical devices (1) including patented syringes, stopcock and sampling devices.

Vectorio is dedicated to Lipiodol Ultra Fluid Injection for imaging of liver tumors in adults with known hepatocellular carcinoma during interventional oncology procedures.

HCC is the most common primary liver cancer and is the fourth biggest cause of death due to cancer worldwide (2).

This medical device:

  • Is 24 hours Lipiodol Ultra Fluid resistant (1)
  • Contains Patented 3-way stopcock with 4 connections offering possibility of "On-table Refill & optimized injection control" (interventional radiologists have the possibility of refill without disconnection from the micro-catheter)
  • Includes all devices in one set
  • Is user-friendly and allows ergonomic and quick device set-up.

Designed and manufactured in France, Vectorio started its commercial launch in September 2017 in European countries. Today, Vectorio for imaging of HCC is registered in Canada & Germany. Vectorio is also registered in 25 countries where cTACE procedures are approved for Lipiodol Ultra Fluid (3,4).

References

  1. Test report (E17-41) - Verification report of the device's functionality after 24h exposure to Lipiodol
  2. WHO - Globocan 2018 (IARC) Global Cancer Observatory.
  3. Vectorio® is registered for HCC imaging in Canada and Germany. Vectorio® is also registered for cTACE in EMEA (Austria, Belgium, Czech Republic, Denmark, France, Hungary, Ireland, Luxembourg, Portugal, Switzerland, The Netherlands, Turkey), Americas (Argentina, Brazil, Ecuador, Mexico, Peru) and Asia-Pacific (Australia, Hong Kong, India, New Zealand, South Korea, Taiwan, Thailand, Vietnam).
  4. Countries in which cTACE indication is registered for Lipiodol® Ultra Fluid: EMEA (Austria, Belgium, Czech Republic, Denmark, France, Hungary, Iran, Ireland, Luxembourg, Portugal, Switzerland, The Netherlands, Tunisia, Turkey), Americas (Argentina, Colombia, Brazil, Chile, Mexico, Peru, Uruguay), Asia-Pacific (Australia, Brunei Darussalam, Cambodia, Hong Kong, India, Mongolia, New Zealand, Philippines, South Korea, Sri Lanka, Taiwan, Thailand, Vietnam). Countries in which HCC imaging indication is registered for Lipiodol® Ultra Fluid: Canada, Germany, United States of America.
Back To Top

Guerbet's Vectorio for Interventional Oncology Is Approved in Canada.  Appl Radiol. 

By News Release| May 19, 2020

About the Author

News Release

News Release



Copyright © Anderson Publishing 2020